This week, biosimilar developer Coherus announced that it has resubmitted a Biologics License Application (BLA) for CHS-1701, a pegfilgrastim biosimilar candidate referencing Neulasta.
This week, biosimilar developer Coherus announced that it has resubmitted a Biologics License Application (BLA) for CHS-1701, a pegfilgrastim biosimilar candidate referencing Neulasta.
“The CHS-1701 BLA resubmission marks a significant milestone in our ongoing transition to a commercial company as we tightly focus on execution of our strategic plan. Pegfilgrastim is the largest selling oncology product in the [United States], and CHS-1701 is the cornerstone of our oncology franchise. We believe we have a strong competitive position with this product, exemplified by our comprehensive clinical immunogenicity data as well as our excellent analytical biosimilarity data,” said Denny Lanfear, president and CEO of Coherus Biosciences in a statement to investors.
In June 2017, Coherus announced that the FDA had issued a Complete Response Letter (CRL) for its proposed pegfilgrastim biosimilar, requesting that the company perform a reanalysis of a subset of samples with a revised immunogenicity assay as well as additional manufacturing information.
The newly submitted BLA is supported by data from analytical, pharmacokinetic, pharmacodynamics, and immunogenicity studies comparing CHS-1701 with the reference product. The updated application also integrates the requested immunogenicity data requested by the FDA.
This resubmission is the latest in a streak of good news for Coherus’ pegfilgrastim candidate. In March, a Delaware court judge granted Coherus’ motion to dismiss a lawsuit brought by Amgen over alleged infringement of a patent covering the reference pegfilgrastim. The patent that was disputed, US patent 8,273,707, covered a process for purifying proteins during which 2 specific salts are used in a loading solution.
According to the court, Amgen previously acknowledged that Coherus did not “literally infringe” on the patent, and “the facts in the prosecution history here are undisputed.”
The company hopes to launch the biosimilar in the US market by mid-2018 and is also anticipating approval for the drug from the European Medicines Agency in the second half of this year.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.